董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Susan Podlogar | 女 | Independent Director | 62 | 23.90万美元 | 4.63 | 2026-08-24 |
| Ryan Saadi | 男 | Director,Chairperson of the Board and Chief Executive Officer | 61 | 1042.10万美元 | 370.96 | 2026-08-24 |
| Jeffrey Feike | 男 | Independent Director | 76 | 23.90万美元 | 5.40 | 2026-08-24 |
| Keow Lin Goh | 女 | Independent Director | 54 | 23.90万美元 | 4.63 | 2026-08-24 |
| Curtis Patton | 男 | Independent Director | 91 | 23.90万美元 | 6.18 | 2026-08-24 |
| Susan Podlogar | 女 | Independent Director | 62 | 未披露 | 未持股 | 2026-08-24 |
| Victor Sordillo | 男 | Independent Director | 73 | 47.81万美元 | 4.91 | 2026-08-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ryan Saadi | 男 | Director,Chairperson of the Board and Chief Executive Officer | 61 | 1042.10万美元 | 370.96 | 2026-08-24 |
| Kirti Desai | 男 | Chief Financial Officer | 69 | 123.00万美元 | 24.30 | 2026-08-24 |
| Neal Flomenberg | 男 | Chief Scientific Officer and Global R and D Lead | 72 | 72.20万美元 | 7.45 | 2026-08-24 |
| Sadiq Khan | 男 | Chief Commercial Officer | 64 | 未披露 | 未持股 | 2026-08-24 |
董事简历
中英对照 | 中文 | 英文- Susan Podlogar
-
Susan Podlogar，大都会人寿公司执行副总裁兼首席人力资源官，2017年7月至今。强生医疗器械、医药和消费品公司（2016年5月至2017年6月）全球医疗器械人力资源副总裁。EMEA人力资源副总裁，全球Total Rewards，强生（2015年1月-2016年5月）。
Susan Podlogar,served as the Executive Vice President, Chief Human Resources Officer at MetLife from July 2017 until her retirement in June 2024. Prior to MetLife, Ms. Podlogar spent 16 years at Johnson & Johnson in various leadership roles, including Global Head, Human Resources Medical Devices; Global Head of Total Rewards and Head Human Resources for Europe, the Middle East, and Africa; and Global Head, Human Resources and Communications Pharmaceutical R&D. Early career highlights include positions with Bayer Pharmaceutical, Bristol-Myers Squibb, and William M. Mercer. She holds an MBA from the University of South Florida and a bachelor's degree with a double major in Labor and Industrial Relations and Business Administration from the University of Wisconsin-Parkside. - Susan Podlogar，大都会人寿公司执行副总裁兼首席人力资源官，2017年7月至今。强生医疗器械、医药和消费品公司（2016年5月至2017年6月）全球医疗器械人力资源副总裁。EMEA人力资源副总裁，全球Total Rewards，强生（2015年1月-2016年5月）。
- Susan Podlogar,served as the Executive Vice President, Chief Human Resources Officer at MetLife from July 2017 until her retirement in June 2024. Prior to MetLife, Ms. Podlogar spent 16 years at Johnson & Johnson in various leadership roles, including Global Head, Human Resources Medical Devices; Global Head of Total Rewards and Head Human Resources for Europe, the Middle East, and Africa; and Global Head, Human Resources and Communications Pharmaceutical R&D. Early career highlights include positions with Bayer Pharmaceutical, Bristol-Myers Squibb, and William M. Mercer. She holds an MBA from the University of South Florida and a bachelor's degree with a double major in Labor and Industrial Relations and Business Administration from the University of Wisconsin-Parkside.
- Ryan Saadi
-
Ryan Saadi自2024年2月起担任首席执行官兼董事长，自2020年6月起担任Tevogen Bio首席执行官兼董事长。自2021年以来，萨阿迪博士一直是耶鲁大学公共卫生学院领导委员会的成员。在创立Tevogen Bio之前，Saadi博士在2018年至2019年期间担任CSL Behring（一家生产血浆衍生和重组治疗产品的生物制药公司）的证据、市场准入和战略定价全球副总裁。在加入CSL Behring之前，Saadi博士曾于2012年至2018年担任杨森市场准入和政策、肿瘤科全球主管，并于2008年至2012年担任强生 Cordis业务负责健康政策、报销、战略定价和市场准入的全球副总裁。此前，Saadi博士曾担任健赞健康结果与定价全球副总裁，以及赛诺菲安万特肿瘤、骨和关节炎产品组合健康结果与市场准入全球负责人。从2010年到2019年，Saadi博士担任CMS医疗保险证据开发和覆盖咨询委员会的投票成员，该委员会就临床主题向CMS提供独立指导和专家建议。
Ryan Saadi has served as Chief Executive Officer and Chairperson since February 2024, and served as Chief Executive Officer and Chairperson of Tevogen Bio beginning in June 2020. Dr. Saadi has been a member of the Leadership Council of the Yale School of Public Health since 2021. Prior to founding Tevogen Bio, Dr. Saadi was the Global Vice President of Evidence, Market Access, and Strategic Pricing for CSL Behring, a biopharmaceutical company that manufactures plasma derived and recombinant therapeutic products, from 2018 to 2019. Before CSL Behring, Dr. Saadi served as Global Head, Market Access and Policy, Oncology for Janssen from 2012 to 2018 and Worldwide Vice President, Health Policy, Reimbursement, Strategic Pricing and Market Access for Johnson & Johnson's Cordis business from 2008 to 2012. Earlier, Dr. Saadi was Global Vice President, Health Outcomes & Pricing for Genzyme and Global Head, Health Outcomes and Market Access for Sanofi Aventis' oncology, bone and arthritis product portfolio. From 2010 through 2019, Dr. Saadi served as a Voting Member of the CMS Medicare Evidence Development & Coverage Advisory Committee, which provides independent guidance and expert advice to CMS on clinical topics. - Ryan Saadi自2024年2月起担任首席执行官兼董事长，自2020年6月起担任Tevogen Bio首席执行官兼董事长。自2021年以来，萨阿迪博士一直是耶鲁大学公共卫生学院领导委员会的成员。在创立Tevogen Bio之前，Saadi博士在2018年至2019年期间担任CSL Behring（一家生产血浆衍生和重组治疗产品的生物制药公司）的证据、市场准入和战略定价全球副总裁。在加入CSL Behring之前，Saadi博士曾于2012年至2018年担任杨森市场准入和政策、肿瘤科全球主管，并于2008年至2012年担任强生 Cordis业务负责健康政策、报销、战略定价和市场准入的全球副总裁。此前，Saadi博士曾担任健赞健康结果与定价全球副总裁，以及赛诺菲安万特肿瘤、骨和关节炎产品组合健康结果与市场准入全球负责人。从2010年到2019年，Saadi博士担任CMS医疗保险证据开发和覆盖咨询委员会的投票成员，该委员会就临床主题向CMS提供独立指导和专家建议。
- Ryan Saadi has served as Chief Executive Officer and Chairperson since February 2024, and served as Chief Executive Officer and Chairperson of Tevogen Bio beginning in June 2020. Dr. Saadi has been a member of the Leadership Council of the Yale School of Public Health since 2021. Prior to founding Tevogen Bio, Dr. Saadi was the Global Vice President of Evidence, Market Access, and Strategic Pricing for CSL Behring, a biopharmaceutical company that manufactures plasma derived and recombinant therapeutic products, from 2018 to 2019. Before CSL Behring, Dr. Saadi served as Global Head, Market Access and Policy, Oncology for Janssen from 2012 to 2018 and Worldwide Vice President, Health Policy, Reimbursement, Strategic Pricing and Market Access for Johnson & Johnson's Cordis business from 2008 to 2012. Earlier, Dr. Saadi was Global Vice President, Health Outcomes & Pricing for Genzyme and Global Head, Health Outcomes and Market Access for Sanofi Aventis' oncology, bone and arthritis product portfolio. From 2010 through 2019, Dr. Saadi served as a Voting Member of the CMS Medicare Evidence Development & Coverage Advisory Committee, which provides independent guidance and expert advice to CMS on clinical topics.
- Jeffrey Feike
-
Jeffrey Feike自2024年2月起担任董事会成员，并于2022年8月开始担任Tevogen Bio的董事会成员。Feike先生于2004年9月至2022年6月担任Covenant Health的Fort Loudoun医疗中心的医院院长。在他的整个职业生涯中，飞科先生监督了医院、门诊和紧急医疗服务（“EMS”）系统的发展。Feike先生在州EMS委员会的临床问题委员会中代表东田纳西州，并在东田纳西州地区医疗通讯中心的董事会任职。
Jeffrey Feike has served on Board since February 2024, and served on the board of directors of Tevogen Bio beginning in August 2022. Mr. Feike served as the Hospital President of Covenant Health's Fort Loudoun Medical Center from September 2004 to June 2022. Throughout his career, Mr. Feike has overseen the development of hospitals, outpatient clinics, and emergency medical services ("EMS") systems. Mr. Feike represents East Tennessee on the state EMS Board's Clinical Issues Committee and serves on the board of Regional Medical Communications Center for East Tennessee. - Jeffrey Feike自2024年2月起担任董事会成员，并于2022年8月开始担任Tevogen Bio的董事会成员。Feike先生于2004年9月至2022年6月担任Covenant Health的Fort Loudoun医疗中心的医院院长。在他的整个职业生涯中，飞科先生监督了医院、门诊和紧急医疗服务（“EMS”）系统的发展。Feike先生在州EMS委员会的临床问题委员会中代表东田纳西州，并在东田纳西州地区医疗通讯中心的董事会任职。
- Jeffrey Feike has served on Board since February 2024, and served on the board of directors of Tevogen Bio beginning in August 2022. Mr. Feike served as the Hospital President of Covenant Health's Fort Loudoun Medical Center from September 2004 to June 2022. Throughout his career, Mr. Feike has overseen the development of hospitals, outpatient clinics, and emergency medical services ("EMS") systems. Mr. Feike represents East Tennessee on the state EMS Board's Clinical Issues Committee and serves on the board of Regional Medical Communications Center for East Tennessee.
- Keow Lin Goh
-
Keow Lin Goh自2024年2月起担任董事会成员，并于2022年8月开始担任Tevogen Bio Inc.（n/k/a Tevogen Bio Inc.）（“Tevogen Bio”）的董事会成员。吴博士是Tapestry Networks的合伙人，该公司将不同领域的领导者聚集在一起，以促进经济、社会和组织变革。Goh博士自2009年以来一直担任Tapestry Networks的合伙人，专注于全球医疗保健政策，目标是改善患者的治疗效果。此前，吴博士曾在2003年至2009年期间担任波士顿咨询公司的高级项目负责人，在那里，她与生物技术和制药领域的高级主管在产品开发、研发重组、组织和运营变革举措、并购后的协同效应以及监管问题方面合作。在医疗保健领域的经验。
Keow Lin Goh has served on Board since February 2024, and served on the board of directors of Tevogen Bio Inc. (n/k/a Tevogen Bio Inc.) ("Tevogen Bio") beginning in August 2022. Dr. Goh is a Partner at Tapestry Networks, a company that has together leaders in different sectors in order to facilitate economic, social, and organizational change. Dr. Goh has served as a Partner at Tapestry Networks since 2009 and focuses on global healthcare policy with the goal of improving patient outcomes. Previously, Dr. Goh was a Senior Project Leader at Boston Consulting Group from 2003 through 2009, where she worked with senior biotech and pharmaceutical executives in product development, research and development restructuring, organizational and operational change initiatives, post merger acquisition synergies, and regulatory issues.experience in the healthcare sector. - Keow Lin Goh自2024年2月起担任董事会成员，并于2022年8月开始担任Tevogen Bio Inc.（n/k/a Tevogen Bio Inc.）（“Tevogen Bio”）的董事会成员。吴博士是Tapestry Networks的合伙人，该公司将不同领域的领导者聚集在一起，以促进经济、社会和组织变革。Goh博士自2009年以来一直担任Tapestry Networks的合伙人，专注于全球医疗保健政策，目标是改善患者的治疗效果。此前，吴博士曾在2003年至2009年期间担任波士顿咨询公司的高级项目负责人，在那里，她与生物技术和制药领域的高级主管在产品开发、研发重组、组织和运营变革举措、并购后的协同效应以及监管问题方面合作。在医疗保健领域的经验。
- Keow Lin Goh has served on Board since February 2024, and served on the board of directors of Tevogen Bio Inc. (n/k/a Tevogen Bio Inc.) ("Tevogen Bio") beginning in August 2022. Dr. Goh is a Partner at Tapestry Networks, a company that has together leaders in different sectors in order to facilitate economic, social, and organizational change. Dr. Goh has served as a Partner at Tapestry Networks since 2009 and focuses on global healthcare policy with the goal of improving patient outcomes. Previously, Dr. Goh was a Senior Project Leader at Boston Consulting Group from 2003 through 2009, where she worked with senior biotech and pharmaceutical executives in product development, research and development restructuring, organizational and operational change initiatives, post merger acquisition synergies, and regulatory issues.experience in the healthcare sector.
- Curtis Patton
-
Curtis Patton自2024年2月起担任董事会成员，并于2020年7月开始担任Tevogen Bio的董事会成员。Patton博士是耶鲁大学公共卫生学院的名誉教授，他在那里工作了36年。Patton博士在耶鲁大学期间担任过各种行政职务，包括担任部门主管、微生物疾病流行病学和全球卫生代理主管。在耶鲁大学期间，巴顿博士还担任国际医学研究主任，并担任国际健康委员会主席。
Curtis Patton has served on Board since February 2024, and served on the board of directors of Tevogen Bio beginning in July 2020. Dr. Patton is Professor Emeritus at Yale School of Public Health, where he worked for 36 years. Dr. Patton served in a variety of administrative capacities during his time at Yale, including as Division Head, Epidemiology of Microbial Diseases and Acting Head of Global Health. While at Yale, Dr. Patton also served as the Director of International Medical Studies and was the Chair of the Committee on International Health. - Curtis Patton自2024年2月起担任董事会成员，并于2020年7月开始担任Tevogen Bio的董事会成员。Patton博士是耶鲁大学公共卫生学院的名誉教授，他在那里工作了36年。Patton博士在耶鲁大学期间担任过各种行政职务，包括担任部门主管、微生物疾病流行病学和全球卫生代理主管。在耶鲁大学期间，巴顿博士还担任国际医学研究主任，并担任国际健康委员会主席。
- Curtis Patton has served on Board since February 2024, and served on the board of directors of Tevogen Bio beginning in July 2020. Dr. Patton is Professor Emeritus at Yale School of Public Health, where he worked for 36 years. Dr. Patton served in a variety of administrative capacities during his time at Yale, including as Division Head, Epidemiology of Microbial Diseases and Acting Head of Global Health. While at Yale, Dr. Patton also served as the Director of International Medical Studies and was the Chair of the Committee on International Health.
- Susan Podlogar
-
Susan Podlogar自2024年2月起任职，并于2022年8月开始在Tevogen Bio董事会任职。Podlogar女士最近在提供保险、年金、员工福利和资产管理的金融服务公司大都会人寿公司（“大都会人寿”）监督全球人力资源战略和实践，自2017年起担任大都会人寿的执行副总裁兼首席人力资源官，直至2024年6月退休。在大都会人寿，Podlogar女士除其他外还建立了“未来发展基金的劳动力”，让员工为未来的工作需求做好准备。Podlogar女士还曾在慈善组织大都会人寿基金会的董事会任职。Podlogar女士还自2024年10月起担任全球医疗技术公司LivaNova PLC（纳斯达克：LIVN）的董事会成员。在加入大都会人寿之前，Podlogar女士于2003年至2017年在强生担任过一系列人力资源职务，包括全球人力资源副总裁和人力资源执行委员会成员。
Susan Podlogar has served on Board since February 2024, and served on the board of directors of Tevogen Bio beginning in August 2022. Ms. Podlogar most recently oversaw global human resources strategies and practices at MetLife, Inc., a financial services company providing insurance, annuities, employee benefits, and asset management ("MetLife"), as MetLife's Executive Vice President and Chief Human Resources Officer from 2017 until her retirement in June 2024. At MetLife, Ms. Podlogar among other things established a "Workforce of the Future Development Fund" to prepare employees for future work needs. Ms. Podlogar also served on the board of directors of MetLife Foundation, a philanthropic organization. Ms. Podlogar has also served on the board of directors of LivaNova PLC (Nasdaq: LIVN), a global medical technology company, since October 2024. Prior to her time at MetLife, Ms. Podlogar held a series of human resources roles at Johnson & Johnson from 2003 to 2017, including Global Vice President of Human Resources and member of the Human Resources Executive Committee. - Susan Podlogar自2024年2月起任职，并于2022年8月开始在Tevogen Bio董事会任职。Podlogar女士最近在提供保险、年金、员工福利和资产管理的金融服务公司大都会人寿公司（“大都会人寿”）监督全球人力资源战略和实践，自2017年起担任大都会人寿的执行副总裁兼首席人力资源官，直至2024年6月退休。在大都会人寿，Podlogar女士除其他外还建立了“未来发展基金的劳动力”，让员工为未来的工作需求做好准备。Podlogar女士还曾在慈善组织大都会人寿基金会的董事会任职。Podlogar女士还自2024年10月起担任全球医疗技术公司LivaNova PLC（纳斯达克：LIVN）的董事会成员。在加入大都会人寿之前，Podlogar女士于2003年至2017年在强生担任过一系列人力资源职务，包括全球人力资源副总裁和人力资源执行委员会成员。
- Susan Podlogar has served on Board since February 2024, and served on the board of directors of Tevogen Bio beginning in August 2022. Ms. Podlogar most recently oversaw global human resources strategies and practices at MetLife, Inc., a financial services company providing insurance, annuities, employee benefits, and asset management ("MetLife"), as MetLife's Executive Vice President and Chief Human Resources Officer from 2017 until her retirement in June 2024. At MetLife, Ms. Podlogar among other things established a "Workforce of the Future Development Fund" to prepare employees for future work needs. Ms. Podlogar also served on the board of directors of MetLife Foundation, a philanthropic organization. Ms. Podlogar has also served on the board of directors of LivaNova PLC (Nasdaq: LIVN), a global medical technology company, since October 2024. Prior to her time at MetLife, Ms. Podlogar held a series of human resources roles at Johnson & Johnson from 2003 to 2017, including Global Vice President of Human Resources and member of the Human Resources Executive Committee.
- Victor Sordillo
-
Victor Sordillo自2024年2月起担任董事会成员，并于2023年7月开始担任Tevogen Bio的董事会成员。Sordillo先生自2024年3月起担任Verist，Inc.（前身为Verita CSG，Inc.）的风险咨询服务总监，该公司是一家为商业线路客户提供整体保险和风险管理解决方案的供应商。Sordillo先生此前曾于2017年至2024年3月担任全球专业财产和意外伤害保险和再保险提供商Sompo International的执行副总裁兼风险控制服务总监，并于2016年至2017年担任QBE北美（“QBE”）风险解决方案高级副总裁。在加入QBE之前，Sordillo先生曾在安达保险 NA担任副总裁兼全球技术服务经理，并于2000年至2016年在该公司工作。Sordillo先生是一名注册专业民用和消防工程师和认证安全专业人员。索迪略先生担任新泽西州沃伦市市长超过22年。
Victor Sordillo has served on Board since February 2024, and served on the board of directors of Tevogen Bio beginning in July 2023. Mr. Sordillo has served as Director of Risk Advisory Services at Verist, Inc. (formerly known as Verita CSG, Inc.), a provider of holistic insurance and risk management solutions for commercial line clients, since March 2024. Mr. Sordillo previously served as the Executive Vice President, Director of Risk Control Services of Sompo International, a global specialty provider of property and casualty insurance and reinsurance, from 2017 to March 2024, and as Senior Vice President Risk Solutions of QBE North America ("QBE") from 2016 to 2017. Prior to QBE, Mr. Sordillo served as Vice President and Global Technical Services Manager at Chubb NA, where he worked from 2000 through 2016. Mr. Sordillo is a registered professional civil and fire protection engineer and Certified Safety Professional. Mr. Sordillo served as the mayor of Warren, New Jersey for more than 22 years. - Victor Sordillo自2024年2月起担任董事会成员，并于2023年7月开始担任Tevogen Bio的董事会成员。Sordillo先生自2024年3月起担任Verist，Inc.（前身为Verita CSG，Inc.）的风险咨询服务总监，该公司是一家为商业线路客户提供整体保险和风险管理解决方案的供应商。Sordillo先生此前曾于2017年至2024年3月担任全球专业财产和意外伤害保险和再保险提供商Sompo International的执行副总裁兼风险控制服务总监，并于2016年至2017年担任QBE北美（“QBE”）风险解决方案高级副总裁。在加入QBE之前，Sordillo先生曾在安达保险 NA担任副总裁兼全球技术服务经理，并于2000年至2016年在该公司工作。Sordillo先生是一名注册专业民用和消防工程师和认证安全专业人员。索迪略先生担任新泽西州沃伦市市长超过22年。
- Victor Sordillo has served on Board since February 2024, and served on the board of directors of Tevogen Bio beginning in July 2023. Mr. Sordillo has served as Director of Risk Advisory Services at Verist, Inc. (formerly known as Verita CSG, Inc.), a provider of holistic insurance and risk management solutions for commercial line clients, since March 2024. Mr. Sordillo previously served as the Executive Vice President, Director of Risk Control Services of Sompo International, a global specialty provider of property and casualty insurance and reinsurance, from 2017 to March 2024, and as Senior Vice President Risk Solutions of QBE North America ("QBE") from 2016 to 2017. Prior to QBE, Mr. Sordillo served as Vice President and Global Technical Services Manager at Chubb NA, where he worked from 2000 through 2016. Mr. Sordillo is a registered professional civil and fire protection engineer and Certified Safety Professional. Mr. Sordillo served as the mayor of Warren, New Jersey for more than 22 years.
高管简历
中英对照 | 中文 | 英文- Ryan Saadi
Ryan Saadi自2024年2月起担任首席执行官兼董事长，自2020年6月起担任Tevogen Bio首席执行官兼董事长。自2021年以来，萨阿迪博士一直是耶鲁大学公共卫生学院领导委员会的成员。在创立Tevogen Bio之前，Saadi博士在2018年至2019年期间担任CSL Behring（一家生产血浆衍生和重组治疗产品的生物制药公司）的证据、市场准入和战略定价全球副总裁。在加入CSL Behring之前，Saadi博士曾于2012年至2018年担任杨森市场准入和政策、肿瘤科全球主管，并于2008年至2012年担任强生 Cordis业务负责健康政策、报销、战略定价和市场准入的全球副总裁。此前，Saadi博士曾担任健赞健康结果与定价全球副总裁，以及赛诺菲安万特肿瘤、骨和关节炎产品组合健康结果与市场准入全球负责人。从2010年到2019年，Saadi博士担任CMS医疗保险证据开发和覆盖咨询委员会的投票成员，该委员会就临床主题向CMS提供独立指导和专家建议。
Ryan Saadi has served as Chief Executive Officer and Chairperson since February 2024, and served as Chief Executive Officer and Chairperson of Tevogen Bio beginning in June 2020. Dr. Saadi has been a member of the Leadership Council of the Yale School of Public Health since 2021. Prior to founding Tevogen Bio, Dr. Saadi was the Global Vice President of Evidence, Market Access, and Strategic Pricing for CSL Behring, a biopharmaceutical company that manufactures plasma derived and recombinant therapeutic products, from 2018 to 2019. Before CSL Behring, Dr. Saadi served as Global Head, Market Access and Policy, Oncology for Janssen from 2012 to 2018 and Worldwide Vice President, Health Policy, Reimbursement, Strategic Pricing and Market Access for Johnson & Johnson's Cordis business from 2008 to 2012. Earlier, Dr. Saadi was Global Vice President, Health Outcomes & Pricing for Genzyme and Global Head, Health Outcomes and Market Access for Sanofi Aventis' oncology, bone and arthritis product portfolio. From 2010 through 2019, Dr. Saadi served as a Voting Member of the CMS Medicare Evidence Development & Coverage Advisory Committee, which provides independent guidance and expert advice to CMS on clinical topics.- Ryan Saadi自2024年2月起担任首席执行官兼董事长，自2020年6月起担任Tevogen Bio首席执行官兼董事长。自2021年以来，萨阿迪博士一直是耶鲁大学公共卫生学院领导委员会的成员。在创立Tevogen Bio之前，Saadi博士在2018年至2019年期间担任CSL Behring（一家生产血浆衍生和重组治疗产品的生物制药公司）的证据、市场准入和战略定价全球副总裁。在加入CSL Behring之前，Saadi博士曾于2012年至2018年担任杨森市场准入和政策、肿瘤科全球主管，并于2008年至2012年担任强生 Cordis业务负责健康政策、报销、战略定价和市场准入的全球副总裁。此前，Saadi博士曾担任健赞健康结果与定价全球副总裁，以及赛诺菲安万特肿瘤、骨和关节炎产品组合健康结果与市场准入全球负责人。从2010年到2019年，Saadi博士担任CMS医疗保险证据开发和覆盖咨询委员会的投票成员，该委员会就临床主题向CMS提供独立指导和专家建议。
- Ryan Saadi has served as Chief Executive Officer and Chairperson since February 2024, and served as Chief Executive Officer and Chairperson of Tevogen Bio beginning in June 2020. Dr. Saadi has been a member of the Leadership Council of the Yale School of Public Health since 2021. Prior to founding Tevogen Bio, Dr. Saadi was the Global Vice President of Evidence, Market Access, and Strategic Pricing for CSL Behring, a biopharmaceutical company that manufactures plasma derived and recombinant therapeutic products, from 2018 to 2019. Before CSL Behring, Dr. Saadi served as Global Head, Market Access and Policy, Oncology for Janssen from 2012 to 2018 and Worldwide Vice President, Health Policy, Reimbursement, Strategic Pricing and Market Access for Johnson & Johnson's Cordis business from 2008 to 2012. Earlier, Dr. Saadi was Global Vice President, Health Outcomes & Pricing for Genzyme and Global Head, Health Outcomes and Market Access for Sanofi Aventis' oncology, bone and arthritis product portfolio. From 2010 through 2019, Dr. Saadi served as a Voting Member of the CMS Medicare Evidence Development & Coverage Advisory Committee, which provides independent guidance and expert advice to CMS on clinical topics.
- Kirti Desai
Kirti Desai是美利坚合众国公民。德赛先生为发行人的首席财务官。
Kirti Desai has served as Chief Financial Officer since February 2024, and served as Chief Financial Officer of Tevogen Bio beginning in June 2020. Mr. Desai previously served as President of Star Accounting Services Inc., an accounting firm providing accounting and tax services to businesses and individuals, from January 2005 to December 2021. Mr. Desai is a certified public accountant. Mr. Desai also serves as the Treasurer of Shrimad Rajchandra Mission Dharampur (USA) Inc., a community outreach and development nonprofit.- Kirti Desai是美利坚合众国公民。德赛先生为发行人的首席财务官。
- Kirti Desai has served as Chief Financial Officer since February 2024, and served as Chief Financial Officer of Tevogen Bio beginning in June 2020. Mr. Desai previously served as President of Star Accounting Services Inc., an accounting firm providing accounting and tax services to businesses and individuals, from January 2005 to December 2021. Mr. Desai is a certified public accountant. Mr. Desai also serves as the Treasurer of Shrimad Rajchandra Mission Dharampur (USA) Inc., a community outreach and development nonprofit.
- Neal Flomenberg
Neal Flomenberg自2024年2月起担任首席科学官和全球研发主管，并于2022年7月开始担任Tevogen Bio的首席科学官和全球研发主管。在加入Tevogen Bio之前，Flomenberg博士于2008年至2022年7月担任托马斯杰斐逊大学Sidney Kimmel医学院内科肿瘤学系教授和系主任，并于2015年至2022年7月担任托马斯杰斐逊大学Sidney Kimmel癌症中心副主任。在担任这些职务之前，弗洛门贝格博士在学术界、医院和研究机构担任过多个领导职务。Flomenberg博士的职业生涯一直专注于血癌，尤其是那些需要骨髓或外周血干细胞移植的癌症，他撰写了超过175篇同行评审的出版物。在杰斐逊，Flomenberg博士还保持着积极的医疗实践，在加入Tevogen Bio之前的15年多时间里，他不断被列入费城杂志的“费城顶级医生”名单。
Neal Flomenberg has served as Chief Scientific Officer and Global R&D Lead since February 2024, and served as Chief Scientific Officer and Global R&D Lead of Tevogen Bio beginning in July 2022. Prior to joining Tevogen Bio, Dr. Flomenberg served as professor and Chair of the Department of Medical Oncology at Sidney Kimmel Medical College of Thomas Jefferson University from 2008 to July 2022 and Deputy Director of Thomas Jefferson University's Sidney Kimmel Cancer Center from 2015 to July 2022. Prior to those positions, Dr. Flomenberg held a number of leadership roles in the academia, hospital, and research settings. Dr. Flomenberg's career has focused on blood cancers, particularly those requiring bone marrow or peripheral blood stem cell transplants, and he has authored over 175 peer reviewed publications. At Jefferson, Dr. Flomenberg also maintained an active medical practice and was continually listed in Philadelphia Magazine's "Top Doctors in Philadelphia" for more than 15 years prior to joining Tevogen Bio.- Neal Flomenberg自2024年2月起担任首席科学官和全球研发主管，并于2022年7月开始担任Tevogen Bio的首席科学官和全球研发主管。在加入Tevogen Bio之前，Flomenberg博士于2008年至2022年7月担任托马斯杰斐逊大学Sidney Kimmel医学院内科肿瘤学系教授和系主任，并于2015年至2022年7月担任托马斯杰斐逊大学Sidney Kimmel癌症中心副主任。在担任这些职务之前，弗洛门贝格博士在学术界、医院和研究机构担任过多个领导职务。Flomenberg博士的职业生涯一直专注于血癌，尤其是那些需要骨髓或外周血干细胞移植的癌症，他撰写了超过175篇同行评审的出版物。在杰斐逊，Flomenberg博士还保持着积极的医疗实践，在加入Tevogen Bio之前的15年多时间里，他不断被列入费城杂志的“费城顶级医生”名单。
- Neal Flomenberg has served as Chief Scientific Officer and Global R&D Lead since February 2024, and served as Chief Scientific Officer and Global R&D Lead of Tevogen Bio beginning in July 2022. Prior to joining Tevogen Bio, Dr. Flomenberg served as professor and Chair of the Department of Medical Oncology at Sidney Kimmel Medical College of Thomas Jefferson University from 2008 to July 2022 and Deputy Director of Thomas Jefferson University's Sidney Kimmel Cancer Center from 2015 to July 2022. Prior to those positions, Dr. Flomenberg held a number of leadership roles in the academia, hospital, and research settings. Dr. Flomenberg's career has focused on blood cancers, particularly those requiring bone marrow or peripheral blood stem cell transplants, and he has authored over 175 peer reviewed publications. At Jefferson, Dr. Flomenberg also maintained an active medical practice and was continually listed in Philadelphia Magazine's "Top Doctors in Philadelphia" for more than 15 years prior to joining Tevogen Bio.
- Sadiq Khan
Sadiq Khan自2024年2月起担任首席商务官，2022年4月起担任Tevogen Bio首席商务官。此前，Khan先生曾于2014年至2022年3月在公立研究型大学新泽西理工学院（“NJIT”）及其子公司担任过多个职务。最近，Khan先生于2018年9月至2022年3月期间担任BioCentriq的高级董事和运营与业务规划执行董事，BioCentriq是新泽西州创新研究所（“NJII”）拥有的营利性细胞和基因治疗合同开发和制造组织，该研究所本身是NJIT的非盈利子公司。在BioCentriq任职期间，Khan是为BioCentriq从NJII分拆做准备的领导团队的一员。Khan先生于2014年至2020年2月期间在NJII担任过多个职务，包括从2018年开始担任Biopharma Innovation业务发展总监，在那里他致力于促进生物制药领域的学术、政府和行业合作。从2008年到2018年3月，Khan先生还担任Pharmique Health LLC的创始人和首席策略师，就战略商业规划和其他事项为企业提供建议。此前，Khan co先生创立了Tegelix Therapeutics，这是一家现已倒闭的制药公司，曾在Hoechst Marion Roussel、Aventis以及随后的赛诺菲 Aventis担任过各种区域和全球商业化和联盟管理职务。
Sadiq Khan has served as Chief Commercial Officer since February 2024, and served as Chief Commercial Officer of Tevogen Bio beginning in April 2022. Previously, Mr. Khan held several roles at the New Jersey Institute of Technology ("NJIT"), a public research university, and its subsidiaries from 2014 to March 2022. Most recently, Mr. Khan served as Senior Director and then Executive Director of Operations & Business Planning at BioCentriq, a for profit cell and gene therapy contract development and manufacturing organization owned by New Jersey Innovation Institute ("NJII"), which was itself a non profit subsidiary of NJIT, from September 2018 to March 2022. While at BioCentriq, Mr. Khan was part of the leadership team that prepared BioCentriq for its spin off from NJII. Mr. Khan held several roles at NJII from 2014 to February 2020, including Director of Business Development, Biopharma Innovation beginning in 2018, where he worked to facilitate academic, government, and industry collaboration in the biopharmaceutical field. From 2008 to March 2018, Mr. Khan also acted as Founder and Chief Strategist for Pharmique Health LLC, where he advised corporations on strategic commercial planning and other matters. Previously, Mr. Khan co founded Tegelix Therapeutics, a now defunct pharmaceutical company, and held various regional and global commercialization and alliance management roles at Hoechst Marion Roussel, Aventis, and then Sanofi Aventis.- Sadiq Khan自2024年2月起担任首席商务官，2022年4月起担任Tevogen Bio首席商务官。此前，Khan先生曾于2014年至2022年3月在公立研究型大学新泽西理工学院（“NJIT”）及其子公司担任过多个职务。最近，Khan先生于2018年9月至2022年3月期间担任BioCentriq的高级董事和运营与业务规划执行董事，BioCentriq是新泽西州创新研究所（“NJII”）拥有的营利性细胞和基因治疗合同开发和制造组织，该研究所本身是NJIT的非盈利子公司。在BioCentriq任职期间，Khan是为BioCentriq从NJII分拆做准备的领导团队的一员。Khan先生于2014年至2020年2月期间在NJII担任过多个职务，包括从2018年开始担任Biopharma Innovation业务发展总监，在那里他致力于促进生物制药领域的学术、政府和行业合作。从2008年到2018年3月，Khan先生还担任Pharmique Health LLC的创始人和首席策略师，就战略商业规划和其他事项为企业提供建议。此前，Khan co先生创立了Tegelix Therapeutics，这是一家现已倒闭的制药公司，曾在Hoechst Marion Roussel、Aventis以及随后的赛诺菲 Aventis担任过各种区域和全球商业化和联盟管理职务。
- Sadiq Khan has served as Chief Commercial Officer since February 2024, and served as Chief Commercial Officer of Tevogen Bio beginning in April 2022. Previously, Mr. Khan held several roles at the New Jersey Institute of Technology ("NJIT"), a public research university, and its subsidiaries from 2014 to March 2022. Most recently, Mr. Khan served as Senior Director and then Executive Director of Operations & Business Planning at BioCentriq, a for profit cell and gene therapy contract development and manufacturing organization owned by New Jersey Innovation Institute ("NJII"), which was itself a non profit subsidiary of NJIT, from September 2018 to March 2022. While at BioCentriq, Mr. Khan was part of the leadership team that prepared BioCentriq for its spin off from NJII. Mr. Khan held several roles at NJII from 2014 to February 2020, including Director of Business Development, Biopharma Innovation beginning in 2018, where he worked to facilitate academic, government, and industry collaboration in the biopharmaceutical field. From 2008 to March 2018, Mr. Khan also acted as Founder and Chief Strategist for Pharmique Health LLC, where he advised corporations on strategic commercial planning and other matters. Previously, Mr. Khan co founded Tegelix Therapeutics, a now defunct pharmaceutical company, and held various regional and global commercialization and alliance management roles at Hoechst Marion Roussel, Aventis, and then Sanofi Aventis.